Mekinist 2 mg

Mekinist 2 mg tablets contain trametinib, a medication used to treat certain types of cancer. This oral tablet is manufactured by Novartis Pharmaceuticals Canada Inc. and is available in a 30-tablet pack.

Mekinist 2 mg tablets are primarily used in the treatment of advanced or metastatic melanoma, a type of skin cancer. This medication is often prescribed for patients who have a specific genetic mutation known as BRAF V600E. Trametinib works by inhibiting the MEK protein, which can help slow the growth and spread of cancer cells. Patients should consult their healthcare provider to determine if Mekinist is suitable for their condition.

Common effects of Mekinist 2 mg tablets may include skin rash, diarrhea, and fatigue. Some patients may also experience fever, swelling, or changes in blood pressure. It is important to monitor for any unusual symptoms and report them to a healthcare professional. The severity and frequency of these effects can vary from person to person.

Mekinist 2 mg tablets should be handled with care and stored as directed. This medication is intended for oral use only and should be taken exactly as prescribed. Patients should avoid crushing or breaking the tablets unless instructed to do so. It is crucial to follow the advice of a healthcare provider regarding the administration and storage of Mekinist.

Mekinist 2 mg tablets may interact with other medications, including those that affect the liver's ability to metabolize drugs. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements. Alcohol and certain foods may also affect the efficacy of trametinib, so it is important to discuss any potential interactions with a healthcare professional.